|
Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden
|
|
Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenström's Macroglobulinemia
|
|
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia
|
|
How I Treat Waldenstrom's Macroglobulinemia
|
|
IgA and IgG hypogammaglobulinemia in Waldenström’s macroglobulinemia
|
|
International prognostic scoring system for Waldenstrom's macroglobulinemia
|
|
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia
|
|
Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
|
|
Soluble CD27 Is a Faithful Marker of Disease Burden and Is Unaffected by the Rituximab-Induced IgM Flare, as Well as by Plasmapheresis, in Patients with Waldenström's Macroglobulinemia
|
